You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylphenidate
Accession NumberDB00422  (APRD00657)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]
Structure
Thumb
Synonyms
alpha-Phenyl-2-piperidineacetic acid methyl ester
Daytrana
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidylacetate
Methylphenidan
Methylphenidate
Methylphenidatum
Metilfenidato
MPH
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aptensio XRcapsule, extended release50 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release15 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release60 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release20 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release30 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release10 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release40 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Biphentincapsule (extended release)30 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)80 mgoralPurdue Pharma2007-03-09Not applicableCanada
Biphentincapsule (extended release)40 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)15 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)50 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)20 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)60 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)10 mgoralPurdue Pharma2006-08-01Not applicableCanada
Concertatablet (extended-release)27 mgoralJanssen Inc2005-01-06Not applicableCanada
Concertatablet, extended release54 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)18 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet, extended release36 mg/1oralPhysicians Total Care, Inc.2003-03-20Not applicableUs
Concertatablet, extended release27 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)36 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet, extended release54 mg/1oralPhysicians Total Care, Inc.2003-05-08Not applicableUs
Concertatablet, extended release18 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)54 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet, extended release27 mg/1oralPhysicians Total Care, Inc.2003-11-13Not applicableUs
Concertatablet, extended release36 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet, extended release18 mg/1oralPhysicians Total Care, Inc.2003-03-21Not applicableUs
Daytranapatch20 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch30 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch10 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch15 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Metadate CDcapsule, extended release20 mg/1oralUnither Manufacturing, LLC2003-02-18Not applicableUs
Metadate CDcapsule, extended release20 mg/1oralPhysicians Total Care, Inc.2002-12-23Not applicableUs
Metadate CDcapsule, extended release60 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDcapsule, extended release10 mg/1oralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDcapsule, extended release30 mg/1oralUnither Manufacturing, LLC2003-07-22Not applicableUs
Metadate CDcapsule, extended release30 mg/1oralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDcapsule, extended release50 mg/1oralPhysicians Total Care, Inc.2011-03-02Not applicableUs
Metadate CDcapsule, extended release40 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDcapsule, extended release10 mg/1oralUnither Manufacturing, LLC2003-08-12Not applicableUs
Metadate CDcapsule, extended release50 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Methylintablet, chewable5 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylinsolution5 mg/5mLoralShionogi Inc.2010-11-01Not applicableUs
Methylintablet, chewable10 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylinsolution10 mg/5mLoralShionogi Inc.2010-11-01Not applicableUs
Methylintablet, chewable2.5 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylphenidatecapsule, extended release30 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidatecapsule, extended release40 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidatetablet5 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidatetablet10 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidatetablet20 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidatecapsule, extended release20 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidate HCl Oral Solutionsolution5 mg/5mLoralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate HCl Oral Solutionsolution10 mg/5mLoralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate Hydrochloridetablet54 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralbryant ranch prepack1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralAmerican Health Packaging2015-01-15Not applicableUs
Methylphenidate Hydrochloridetablet36 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet54 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate Hydrochloridetablet36 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release30 mg/1oralKremers Urban Pharmaceuticals Inc.2003-07-22Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release40 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release50 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release10 mg/1oralKremers Urban Pharmaceuticals Inc.2003-08-12Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release60 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release20 mg/1oralKremers Urban Pharmaceuticals Inc.2003-02-18Not applicableUs
Methylphenidate Hydrochloride SRtablet, film coated, extended release20 mg/1oralSandoz Inc1982-03-31Not applicableUs
Methylphenidate Tab 10mgtablet10 mgoralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Methylphenidate Tab 20mgtablet20 mgoralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Novo-methylphenidatetablet10.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidatetablet20.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidatetablet5.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
PHL-methylphenidatetablet20 mgoralPharmel Inc2003-04-21Not applicableCanada
PHL-methylphenidatetablet10 mgoralPharmel Inc2003-04-21Not applicableCanada
PHL-methylphenidatetablet5 mgoralPharmel Inc2003-01-07Not applicableCanada
PMS-methylphenidatetablet5 mgoralPharmascience Inc1997-10-24Not applicableCanada
PMS-methylphenidatetablet10 mgoralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidatetablet20 mgoralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)18 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)27 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)36 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)54 mgoralPharmascience Inc2014-03-03Not applicableCanada
Quillichew ERtablet, chewable, extended release30 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERtablet, chewable, extended release40 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERtablet, chewable, extended release20 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillivant XRpowder, for suspension600 mg/120mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRpowder, for suspension750 mg/150mLoralNext Wave Pharmaceuticals, Inc.2013-01-04Not applicableUs
Quillivant XRpowder, for suspension900 mg/180mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRpowder, for suspension300 mg/60mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Ratio-methylphenidatetablet5 mgoralTeva Canada Limited2003-05-01Not applicableCanada
Ratio-methylphenidatetablet10 mgoralTeva Canada Limited1998-01-22Not applicableCanada
Ratio-methylphenidatetablet20 mgoralTeva Canada Limited1998-01-22Not applicableCanada
Ritalintablet5 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalintablet10 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalintablet20 mg/1oralPhysicians Total Care, Inc.2000-03-10Not applicableUs
Ritalintablet20 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalin 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1956-12-31Not applicableCanada
Ritalin 20mgtablet20 mgoralNovartis Pharmaceuticals Canada Inc1958-12-31Not applicableCanada
Ritalin LAcapsule, extended release60 mg/1oralNovartis Pharmaceuticals Corporation2015-02-01Not applicableUs
Ritalin LAcapsule, extended release20 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release30 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release40 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release10 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin-SR Tab 20mgtablet (extended-release)20 mgoralNovartis Pharmaceuticals Canada Inc1984-12-31Not applicableCanada
Sandoz Methylphenidatetablet10 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Methylphenidatetablet20 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Methylphenidate SRtablet (extended-release)20 mgoralSandoz Canada Incorporated2008-12-23Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)27 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)36 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)54 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)18 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methylphenidatetablet20 mgoralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidatetablet5 mgoralApotex Inc2006-02-01Not applicableCanada
Apo-methylphenidatetablet10 mgoralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidate ERtablet (extended-release)27 mgoralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERtablet (extended-release)36 mgoralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERtablet (extended-release)54 mgoralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERtablet (extended-release)18 mgoralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate SRtablet (extended-release)20 mgoralApotex Inc2005-04-27Not applicableCanada
Metadate ERtablet, extended release20 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Metadate ERtablet, extended release20 mg/1oralUnither Manufacturing, LLC1988-06-01Not applicableUs
Methylphenidatetablet10 mg/1oralPhysicians Total Care, Inc.2005-03-24Not applicableUs
Methylphenidatetablet5 mg/1oralSTAT Rx USA LLC1997-08-29Not applicableUs
Methylphenidatetablet5 mg/1oralPhysicians Total Care, Inc.2009-05-14Not applicableUs
Methylphenidatetablet20 mg/1oralPhysicians Total Care, Inc.2007-10-16Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release30 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridetablet, chewable2.5 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralUnither Manufacturing, LLC1977-12-23Not applicableUs
Methylphenidate Hydrochloridetablet, extended release54 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet, extended release54 mg/1oralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloridetablet, extended release10 mg/1oralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate Hydrochloridetablet, extended release10 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridetablet, chewable2.5 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release40 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridetablet, chewable5 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralbryant ranch prepack2010-02-01Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralAmerican Health Packaging2014-12-01Not applicableUs
Methylphenidate Hydrochloridetablet, chewable5 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridetablet, chewable10 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release30 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate Hydrochloridetablet, chewable10 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet, extended release27 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release27 mg/1oralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralAvera Mc Kennan Hospital2015-03-06Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release40 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridetablet, extended release36 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralPhysicians Total Care, Inc.1994-12-16Not applicableUs
Methylphenidate Hydrochloridetablet, extended release36 mg/1oralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release50 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release60 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release40 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release10 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release20 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release40 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release20 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride ERtablet, extended release10 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride ERtablet, extended release20 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride Extended Releasetablet20 mg/1oralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended Releasetablet10 mg/1oralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule60 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet54 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule30 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule40 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet27 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule10 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule50 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet36 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule20 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Equasym XLNot Available
Medikinet XLNot Available
MetadateNot Available
QuillivantNot Available
RiphenidateNot Available
Rubifen SRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methylphenidate Hydrochloride
Thumb
  • InChI Key: JUMYIBMBTDDLNG-UHFFFAOYNA-N
  • Monoisotopic Mass: 269.118256596
  • Average Mass: 269.767
DBSALT000117
Categories
UNII207ZZ9QZ49
CAS number113-45-1
WeightAverage: 233.3062
Monoisotopic: 233.141578857
Chemical FormulaC14H19NO2
InChI KeyInChIKey=DUGOZIWVEXMGBE-UHFFFAOYSA-N
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
IUPAC Name
methyl 2-phenyl-2-(piperidin-2-yl)acetate
SMILES
COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Aralkylamine
  • Piperidine
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
PharmacodynamicsMethylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Methylphenidate also blocks the reuptake of norepinephrine and dopamine. Its mechanisms appear to be similar to those of dextroamphetamine. Furthermore, it is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer.
Mechanism of actionMethylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.
Related Articles
AbsorptionReadily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically.
Volume of distribution

d-methylphenidate = 2.65 L/kg;
l-methylphenidate = 1.80 L/kg;

Protein bindingBinding to plasma proteins is low (10%-33%).
Metabolism

Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.

Route of eliminationAfter oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (<1%) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as ritalinic acid (60%-86%), the remainder being accounted for by minor metabolites.
Half lifed-methylphenidate = 3-4 hours; l-methylphenidate = 1-3 hours; Ritalinic acid = 3-4 hours;
Clearance

Systemic clearance for Ritalin LA and Ritalin tablets is as follows:
d-methylphenidate= 0.40±0.12 L/h/kg;
l-methylphenidate = 0.73±0.28 L/h/kg;

ToxicitySymptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9663
Caco-2 permeable+0.6564
P-glycoprotein substrateSubstrate0.5466
P-glycoprotein inhibitor INon-inhibitor0.7964
P-glycoprotein inhibitor IINon-inhibitor0.9601
Renal organic cation transporterInhibitor0.532
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5985
CYP450 1A2 substrateNon-inhibitor0.592
CYP450 2C9 inhibitorNon-inhibitor0.897
CYP450 2D6 inhibitorNon-inhibitor0.5245
CYP450 2C19 inhibitorNon-inhibitor0.9265
CYP450 3A4 inhibitorNon-inhibitor0.8539
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9648
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.7718 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8466
hERG inhibition (predictor II)Non-inhibitor0.7491
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Ucb inc
  • Novartis pharmaceuticals corp
  • Mallinckrodt inc
  • Tris pharma inc
  • Ortho mcneil janssen pharmaceutical inc
  • Able laboratories inc
  • Actavis elizabeth llc
  • Watson laboratories inc
  • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral15 mg/1
Capsule (extended release)oral10 mg
Capsule (extended release)oral15 mg
Capsule (extended release)oral20 mg
Capsule (extended release)oral30 mg
Capsule (extended release)oral40 mg
Capsule (extended release)oral50 mg
Capsule (extended release)oral60 mg
Capsule (extended release)oral80 mg
Tablet (extended-release)oral18 mg
Tablet (extended-release)oral27 mg
Tablet (extended-release)oral36 mg
Tablet (extended-release)oral54 mg
Patchtransdermal10 mg/9h
Patchtransdermal15 mg/9h
Patchtransdermal20 mg/9h
Patchtransdermal30 mg/9h
Solutionoral10 mg/5mL
Solutionoral5 mg/5mL
Tabletoral18 mg/1
Tablet, chewableoral10 mg/1
Tablet, chewableoral2.5 mg/1
Tablet, chewableoral5 mg/1
Tablet, extended releaseoral10 mg/1
Tablet, extended releaseoral18 mg/1
Tablet, extended releaseoral20 mg/1
Tablet, extended releaseoral27 mg/1
Tablet, extended releaseoral36 mg/1
Tablet, extended releaseoral54 mg/1
Capsule, extended releaseoral50 mg/1
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsuleoral30 mg/1
Capsuleoral40 mg/1
Capsuleoral50 mg/1
Capsuleoral60 mg/1
Tabletoral27 mg/1
Tabletoral36 mg/1
Tabletoral54 mg/1
Tablet, film coated, extended releaseoral20 mg/1
Tabletoral10.00 mg
Tabletoral20.00 mg
Tabletoral5.00 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral5 mg
Tablet, chewable, extended releaseoral20 mg/1
Tablet, chewable, extended releaseoral30 mg/1
Tablet, chewable, extended releaseoral40 mg/1
Powder, for suspensionoral300 mg/60mL
Powder, for suspensionoral600 mg/120mL
Powder, for suspensionoral750 mg/150mL
Powder, for suspensionoral900 mg/180mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral60 mg/1
Tablet (extended-release)oral20 mg
Prices
Unit descriptionCostUnit
Daytrana 30 15 mg/9hr Patches Box175.64USD box
Daytrana 30 30 mg/9hr Patches Box174.73USD box
Daytrana 30 10 mg/9hr Patches Box172.78USD box
Daytrana 30 20 mg/9hr Patches Box168.72USD box
Methylphenidate hcl powder44.62USD g
Concerta er 54 mg tablet25.45USD tablet
Concerta er 36 mg tablet23.38USD tablet
Concerta er 27 mg tablet22.65USD tablet
Concerta er 18 mg tablet22.11USD tablet
Metadate cd 50 mg capsule7.08USD capsule
Metadate cd 60 mg capsule7.02USD capsule
Concerta 54 mg Controlled Release Tabs6.18USD tab
Metadate cd 40 mg capsule5.77USD capsule
Concerta 36 mg Controlled Release Tabs5.72USD tab
Focalin xr 30 mg capsule5.42USD capsule
Focalin XR 20 mg 24 Hour Capsule5.31USD capsule
Daytrana 10 mg/9 hr patch5.16USD patch
Daytrana 15 mg/9 hr patch5.16USD patch
Daytrana 20 mg/9 hour patch5.16USD patch
Daytrana 30 mg/9 hour patch5.16USD patch
Focalin xr 15 mg capsule5.16USD capsule
Focalin xr 20 mg capsule5.16USD capsule
Focalin XR 30 mg 24 Hour Capsule5.15USD capsule
Focalin xr 10 mg capsule5.02USD capsule
Concerta 18 mg Controlled Release Tabs5.0USD tab
Concerta 27 mg Controlled Release Tabs5.0USD tab
Focalin XR 10 mg 24 Hour Capsule4.96USD capsule
Focalin xr 5 mg capsule4.95USD capsule
Concerta 54 mg tablet sa4.91USD tablet
Focalin XR 15 mg 24 Hour Capsule4.89USD capsule
Focalin XR 5 mg 24 Hour Capsule4.83USD capsule
Ritalin la 40 mg capsule4.55USD capsule
Concerta 36 mg tablet sa4.51USD tablet
Ritalin la 30 mg capsule4.43USD capsule
Ritalin LA 10 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 20 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 30 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 40 mg 24 Hour Capsule4.42USD capsule
Concerta 27 mg tablet sa4.37USD tablet
Ritalin la 10 mg capsule4.33USD capsule
Ritalin la 20 mg capsule4.33USD capsule
Concerta 18 mg tablet sa4.27USD tablet
Metadate cd 20 mg capsule4.24USD capsule
Metadate cd 30 mg capsule4.24USD capsule
Metadate cd 10 mg capsule4.2USD capsule
Methylphenidate er 10 mg tablet3.24USD tablet
Ritalin SR 20 mg Controlled Release Tabs3.0USD tab
Ritalin sr 20 mg tablet2.67USD tablet
Ritalin 20 mg tablet1.87USD tablet
Focalin 10 mg tablet1.7USD tablet
Ritalin 5 mg tablet1.42USD tablet
Metadate er 20 mg tablet1.32USD tablet
Methylin ER 20 mg Controlled Release Tabs1.3USD tab
Ritalin 10 mg tablet1.29USD tablet
Metadate er 10 mg tablet sa1.28USD tablet
Focalin 5 mg tablet1.26USD tablet
Methylphenidate HCl CR 20 mg Controlled Release Tabs1.2USD tab
Methylin er 20 mg tablet1.12USD tablet
Methylphenidate HCl 20 mg tablet1.05USD tablet
Methylin ER 10 mg1.0USD tab
Methylphenidate HCl 10 mg tablet0.95USD tablet
Methylphenidate HCl 5 mg tablet0.94USD tablet
Methylin er 10 mg tablet0.84USD tablet
Focalin 2.5 mg tablet0.76USD tablet
Methylin 20 mg tablet0.69USD tablet
Methylphenidate 20 mg tablet0.69USD tablet
Ritalin 20 mg Tablet0.67USD tablet
Ritalin Sr 20 mg Extended-Release Tablet0.67USD tablet
Methylin 10 mg tablet0.48USD tablet
Methylphenidate 10 mg tablet0.48USD tablet
Ritalin 10 mg Tablet0.38USD tablet
Apo-Methylphenidate 20 mg Tablet0.37USD tablet
Apo-Methylphenidate Sr 20 mg Extended-Release Tablet0.37USD tablet
Pms-Methylphenidate 20 mg Tablet0.37USD tablet
Sandoz Methylphenidate 20 mg Extended-Release Tablet0.37USD tablet
Methylin 5 mg tablet0.33USD tablet
Methylphenidate 5 mg tablet0.33USD tablet
Apo-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 5 mg Tablet0.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2264852 No2005-11-012017-09-16Canada
CA2355644 No2009-01-202019-12-17Canada
US5837284 No1995-12-042015-12-04Us
US5958446 No1992-12-122012-12-12Us
US6210705 No1998-09-302018-09-30Us
US6228398 No1999-11-012019-11-01Us
US6344215 No2000-10-272020-10-27Us
US6348211 No1998-09-302018-09-30Us
US6419960 No1999-12-162019-12-16Us
US6635284 No1995-12-042015-12-04Us
US6919373 Yes1998-01-312018-01-31Us
US6930129 Yes1998-01-312018-01-31Us
US7083808 No1999-12-162019-12-16Us
US7247318 No1999-12-162019-12-16Us
US7431944 No1995-12-042015-12-04Us
US7438930 No1999-12-162019-12-16Us
US7691880 No2004-10-072024-10-07Us
US8062667 No2009-03-292029-03-29Us
US8163798 Yes1998-01-312018-01-31Us
US8202537 No2007-03-152027-03-15Us
US8287903 No2011-02-152031-02-15Us
US8465765 No2011-02-152031-02-15Us
US8563033 No2011-02-152031-02-15Us
US8580310 No1999-12-162019-12-16Us
US8629179 Yes1998-01-312018-01-31Us
US8632802 No2005-10-072025-10-07Us
US8778390 No2011-02-152031-02-15Us
US8956649 No2011-02-152031-02-15Us
US8999386 No2013-04-142033-04-14Us
US9000038 Yes1998-01-312018-01-31Us
US9029416 No1997-07-312017-07-31Us
US9034370 No2005-10-072025-10-07Us
US9040083 No2011-02-152031-02-15Us
US9066869 No1999-12-162019-12-16Us
US9144549 No1997-07-312017-07-31Us
US9295642 No2013-08-142033-08-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point224-226 °CNot Available
water solubility1255mg/LNot Available
logP0.20HANSCH,C ET AL. (1995), pH 7.2
pKa8.77SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP1.47ALOGPS
logP2.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity66.73 m3·mol-1ChemAxon
Polarizability26.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.79 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9100000000-1a9c5badbee827946da1View in MoNA
References
Synthesis Reference

DrugSyn.org

US2512572
General References
  1. Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3. [PubMed:11524026 ]
  2. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98. [PubMed:17201613 ]
  3. Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [PubMed:15661631 ]
  4. Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17. [PubMed:2190251 ]
  5. Shults T, Kownacki AA, Woods WE, Valentine R, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. Am J Vet Res. 1981 May;42(5):722-6. [PubMed:7258793 ]
External Links
ATC CodesN06BA04
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (178 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Methylphenidate.
AbirateroneThe metabolism of Methylphenidate can be decreased when combined with Abiraterone.
AcebutololMethylphenidate may decrease the antihypertensive activities of Acebutolol.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.
AliskirenMethylphenidate may decrease the antihypertensive activities of Aliskiren.
AlprenololMethylphenidate may decrease the antihypertensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Aluminum phosphateAluminum phosphate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmbrisentanMethylphenidate may decrease the antihypertensive activities of Ambrisentan.
AmineptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.
AmiodaroneThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.
AmitriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.
AmlodipineMethylphenidate may decrease the antihypertensive activities of Amlodipine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methylphenidate.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methylphenidate.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.
ArtemetherThe metabolism of Methylphenidate can be decreased when combined with Artemether.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenidate.
AtenololMethylphenidate may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Methylphenidate can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methylphenidate.
BenazeprilMethylphenidate may decrease the antihypertensive activities of Benazepril.
BendroflumethiazideMethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypertensive activities of Methylphenidate.
BepridilMethylphenidate may decrease the antihypertensive activities of Bepridil.
BetaxololMethylphenidate may decrease the antihypertensive activities of Betaxolol.
BetaxololThe metabolism of Methylphenidate can be decreased when combined with Betaxolol.
BethanidineMethylphenidate may decrease the antihypertensive activities of Bethanidine.
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Methylphenidate.
BimatoprostMethylphenidate may decrease the antihypertensive activities of Bimatoprost.
Bismuth SubcitrateBismuth Subcitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
BisoprololMethylphenidate may decrease the antihypertensive activities of Bisoprolol.
BosentanMethylphenidate may decrease the antihypertensive activities of Bosentan.
BretyliumMethylphenidate may decrease the antihypertensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.
BrimonidineMethylphenidate may decrease the antihypertensive activities of Brimonidine.
BupranololMethylphenidate may decrease the antihypertensive activities of Bupranolol.
BupropionThe metabolism of Methylphenidate can be decreased when combined with Bupropion.
Calcium carbonateCalcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
CandesartanMethylphenidate may decrease the antihypertensive activities of Candesartan.
CandoxatrilMethylphenidate may decrease the antihypertensive activities of Candoxatril.
CaptoprilMethylphenidate may decrease the antihypertensive activities of Captopril.
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.
CaroxazoneCaroxazone may increase the hypertensive activities of Methylphenidate.
CarteololMethylphenidate may decrease the antihypertensive activities of Carteolol.
CarvedilolMethylphenidate may decrease the antihypertensive activities of Carvedilol.
CelecoxibThe metabolism of Methylphenidate can be decreased when combined with Celecoxib.
CeliprololMethylphenidate may decrease the antihypertensive activities of Celiprolol.
ChloroquineThe metabolism of Methylphenidate can be decreased when combined with Chloroquine.
ChlorothiazideMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.
ChlorthalidoneMethylphenidate may decrease the antihypertensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Methylphenidate can be decreased when combined with Cholecalciferol.
CilazaprilMethylphenidate may decrease the antihypertensive activities of Cilazapril.
CimetidineCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
CinacalcetThe metabolism of Methylphenidate can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Methylphenidate can be decreased when combined with Citalopram.
ClemastineThe metabolism of Methylphenidate can be decreased when combined with Clemastine.
ClobazamThe metabolism of Methylphenidate can be decreased when combined with Clobazam.
ClomipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.
ClomipramineThe metabolism of Methylphenidate can be decreased when combined with Clomipramine.
ClonidineMethylphenidate may decrease the antihypertensive activities of Clonidine.
ClotrimazoleThe metabolism of Methylphenidate can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.
CobicistatThe serum concentration of Methylphenidate can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Methylphenidate can be decreased when combined with Cocaine.
CryptenamineMethylphenidate may decrease the antihypertensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.
CyclothiazideMethylphenidate may decrease the antihypertensive activities of Cyclothiazide.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.
DarifenacinThe metabolism of Methylphenidate can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Methylphenidate can be increased when it is combined with Darunavir.
DebrisoquinMethylphenidate may decrease the antihypertensive activities of Debrisoquin.
DelavirdineThe metabolism of Methylphenidate can be decreased when combined with Delavirdine.
DeserpidineMethylphenidate may decrease the antihypertensive activities of Deserpidine.
DesfluraneMethylphenidate may increase the hypertensive activities of Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
DesipramineThe metabolism of Methylphenidate can be decreased when combined with Desipramine.
DiazoxideMethylphenidate may decrease the antihypertensive activities of Diazoxide.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Methylphenidate.
DiltiazemMethylphenidate may decrease the antihypertensive activities of Diltiazem.
DiphenhydramineThe metabolism of Methylphenidate can be decreased when combined with Diphenhydramine.
DorzolamideMethylphenidate may decrease the antihypertensive activities of Dorzolamide.
DosulepinThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.
DoxazosinMethylphenidate may decrease the antihypertensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
DoxepinDoxepin can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DronedaroneThe metabolism of Methylphenidate can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.
DuloxetineThe metabolism of Methylphenidate can be decreased when combined with Duloxetine.
EfonidipineMethylphenidate may decrease the antihypertensive activities of Efonidipine.
EliglustatThe metabolism of Methylphenidate can be decreased when combined with Eliglustat.
EnalaprilMethylphenidate may decrease the antihypertensive activities of Enalapril.
EnalaprilatMethylphenidate may decrease the antihypertensive activities of Enalaprilat.
EnfluraneMethylphenidate may increase the hypertensive activities of Enflurane.
EpinastineEpinastine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
EpoprostenolMethylphenidate may decrease the antihypertensive activities of Epoprostenol.
EprosartanMethylphenidate may decrease the antihypertensive activities of Eprosartan.
EsmirtazapineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Esmirtazapine.
EsomeprazoleEsomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate.
FamotidineFamotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
FelodipineMethylphenidate may decrease the antihypertensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate.
FenoldopamMethylphenidate may decrease the antihypertensive activities of Fenoldopam.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.
FluoxetineThe metabolism of Methylphenidate can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.
FluvoxamineThe metabolism of Methylphenidate can be decreased when combined with Fluvoxamine.
FosinoprilMethylphenidate may decrease the antihypertensive activities of Fosinopril.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.
FurazolidoneFurazolidone may increase the hypertensive activities of Methylphenidate.
GuanabenzMethylphenidate may decrease the antihypertensive activities of Guanabenz.
GuanadrelMethylphenidate may decrease the antihypertensive activities of Guanadrel.
GuanethidineMethylphenidate may decrease the antihypertensive activities of Guanethidine.
GuanfacineMethylphenidate may decrease the antihypertensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
HalothaneMethylphenidate may increase the hypertensive activities of Halothane.
HexamethoniumMethylphenidate may decrease the antihypertensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypertensive activities of Methylphenidate.
HydralazineMethylphenidate may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.
HydroflumethiazideMethylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.
ImipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
ImipramineThe metabolism of Methylphenidate can be decreased when combined with Imipramine.
IndapamideMethylphenidate may decrease the antihypertensive activities of Indapamide.
IndenololMethylphenidate may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Methylphenidate can be decreased when combined with Indinavir.
IndoraminMethylphenidate may decrease the antihypertensive activities of Indoramin.
Ioflupane I-123Methylphenidate may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the hypertensive activities of Methylphenidate.
IproniazidIproniazid may increase the hypertensive activities of Methylphenidate.
IrbesartanMethylphenidate may decrease the antihypertensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Methylphenidate.
IsofluraneMethylphenidate may increase the hypertensive activities of Isoflurane.
IsoniazidThe metabolism of Methylphenidate can be decreased when combined with Isoniazid.
IsradipineMethylphenidate may decrease the antihypertensive activities of Isradipine.
KetoconazoleThe metabolism of Methylphenidate can be decreased when combined with Ketoconazole.
LabetalolMethylphenidate may decrease the antihypertensive activities of Labetalol.
LacidipineMethylphenidate may decrease the antihypertensive activities of Lacidipine.
LansoprazoleLansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
LatanoprostMethylphenidate may decrease the antihypertensive activities of Latanoprost.
LercanidipineMethylphenidate may decrease the antihypertensive activities of Lercanidipine.
LisinoprilMethylphenidate may decrease the antihypertensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.
LofexidineMethylphenidate may decrease the antihypertensive activities of Lofexidine.
LopinavirThe metabolism of Methylphenidate can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Methylphenidate can be decreased when combined with Lorcaserin.
LosartanMethylphenidate may decrease the antihypertensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.
LumefantrineThe metabolism of Methylphenidate can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
MacitentanMethylphenidate may decrease the antihypertensive activities of Macitentan.
MagaldrateMagaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium carbonateMagnesium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium hydroxideMagnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium oxideMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium TrisilicateMagnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
ManidipineMethylphenidate may decrease the antihypertensive activities of Manidipine.
MebanazineMebanazine may increase the hypertensive activities of Methylphenidate.
MecamylamineMethylphenidate may decrease the antihypertensive activities of Mecamylamine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.
MethadoneThe metabolism of Methylphenidate can be decreased when combined with Methadone.
MethanthelineMethantheline can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.
MethoxyfluraneMethylphenidate may increase the hypertensive activities of Methoxyflurane.
MethyldopaMethylphenidate may decrease the antihypertensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypertensive activities of Methylphenidate.
MetiamideMetiamide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetipranololMethylphenidate may decrease the antihypertensive activities of Metipranolol.
MetolazoneMethylphenidate may decrease the antihypertensive activities of Metolazone.
MetoprololMethylphenidate may decrease the antihypertensive activities of Metoprolol.
MetoprololThe metabolism of Methylphenidate can be decreased when combined with Metoprolol.
MibefradilMethylphenidate may decrease the antihypertensive activities of Mibefradil.
MinaprineMinaprine may increase the hypertensive activities of Methylphenidate.
MinoxidilMethylphenidate may decrease the antihypertensive activities of Minoxidil.
MirabegronThe metabolism of Methylphenidate can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Mirtazapine.
MoclobemideMoclobemide may increase the hypertensive activities of Methylphenidate.
MoexiprilMethylphenidate may decrease the antihypertensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.
MoxonidineMethylphenidate may decrease the antihypertensive activities of Moxonidine.
NadololMethylphenidate may decrease the antihypertensive activities of Nadolol.
NebivololMethylphenidate may decrease the antihypertensive activities of Nebivolol.
NevirapineThe metabolism of Methylphenidate can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypertensive activities of Methylphenidate.
NicardipineMethylphenidate may decrease the antihypertensive activities of Nicardipine.
NicardipineThe metabolism of Methylphenidate can be decreased when combined with Nicardipine.
NicorandilMethylphenidate may decrease the antihypertensive activities of Nicorandil.
NiguldipineMethylphenidate may decrease the antihypertensive activities of Niguldipine.
NilotinibThe metabolism of Methylphenidate can be decreased when combined with Nilotinib.
NilvadipineMethylphenidate may decrease the antihypertensive activities of Nilvadipine.
NimodipineMethylphenidate may decrease the antihypertensive activities of Nimodipine.
NisoldipineMethylphenidate may decrease the antihypertensive activities of Nisoldipine.
NitrendipineMethylphenidate may decrease the antihypertensive activities of Nitrendipine.
NitroprussideMethylphenidate may decrease the antihypertensive activities of Nitroprusside.
Nitrous oxideMethylphenidate may increase the hypertensive activities of Nitrous oxide.
NizatidineNizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
NortriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
OctamoxinOctamoxin may increase the hypertensive activities of Methylphenidate.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.
OlmesartanMethylphenidate may decrease the antihypertensive activities of Olmesartan.
OmapatrilatMethylphenidate may decrease the antihypertensive activities of Omapatrilat.
OmeprazoleOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.
OxprenololMethylphenidate may decrease the antihypertensive activities of Oxprenolol.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
PanobinostatThe metabolism of Methylphenidate can be decreased when combined with Panobinostat.
PantoprazolePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
PargylineMethylphenidate may decrease the antihypertensive activities of Pargyline.
PargylinePargyline may increase the hypertensive activities of Methylphenidate.
ParoxetineThe metabolism of Methylphenidate can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololMethylphenidate may decrease the antihypertensive activities of Penbutolol.
PentoliniumMethylphenidate may decrease the antihypertensive activities of Pentolinium.
PerindoprilMethylphenidate may decrease the antihypertensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methylphenidate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.
PhenelzinePhenelzine may increase the hypertensive activities of Methylphenidate.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Methylphenidate.
PheniprazinePheniprazine may increase the hypertensive activities of Methylphenidate.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.
PhenoxybenzamineMethylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Methylphenidate.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Methylphenidate.
PhentolamineMethylphenidate may decrease the antihypertensive activities of Phentolamine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.
PinacidilMethylphenidate may decrease the antihypertensive activities of Pinacidil.
PindololMethylphenidate may decrease the antihypertensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.
PirlindolePirlindole may increase the hypertensive activities of Methylphenidate.
PivhydrazinePivhydrazine may increase the hypertensive activities of Methylphenidate.
PolythiazideMethylphenidate may decrease the antihypertensive activities of Polythiazide.
PrazosinMethylphenidate may decrease the antihypertensive activities of Prazosin.
PrimidoneThe serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Methylphenidate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate.
PropranololMethylphenidate may decrease the antihypertensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
QuinaprilMethylphenidate may decrease the antihypertensive activities of Quinapril.
QuinidineThe metabolism of Methylphenidate can be decreased when combined with Quinidine.
QuinineThe metabolism of Methylphenidate can be decreased when combined with Quinine.
RabeprazoleRabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RamiprilMethylphenidate may decrease the antihypertensive activities of Ramipril.
RanitidineRanitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RanolazineThe metabolism of Methylphenidate can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypertensive activities of Methylphenidate.
RemikirenMethylphenidate may decrease the antihypertensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.
RescinnamineMethylphenidate may decrease the antihypertensive activities of Rescinnamine.
ReserpineMethylphenidate may decrease the antihypertensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenidate.
RiociguatMethylphenidate may decrease the antihypertensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.
RitonavirThe metabolism of Methylphenidate can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Methylphenidate can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Methylphenidate can be decreased when combined with Ropinirole.
Roxatidine acetateRoxatidine acetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
SafrazineSafrazine may increase the hypertensive activities of Methylphenidate.
SaprisartanMethylphenidate may decrease the antihypertensive activities of Saprisartan.
SelegilineSelegiline may increase the hypertensive activities of Methylphenidate.
SelexipagMethylphenidate may decrease the antihypertensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.
SertralineThe metabolism of Methylphenidate can be decreased when combined with Sertraline.
SevofluraneMethylphenidate may increase the hypertensive activities of Sevoflurane.
SitaxentanMethylphenidate may decrease the antihypertensive activities of Sitaxentan.
SpiraprilMethylphenidate may decrease the antihypertensive activities of Spirapril.
StiripentolThe metabolism of Methylphenidate can be decreased when combined with Stiripentol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.
TAK-390MRTAK-390MR can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
TelmisartanMethylphenidate may decrease the antihypertensive activities of Telmisartan.
TemocaprilMethylphenidate may decrease the antihypertensive activities of Temocapril.
TerbinafineThe metabolism of Methylphenidate can be decreased when combined with Terbinafine.
TerlipressinMethylphenidate may decrease the antihypertensive activities of Terlipressin.
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methylphenidate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.
TianeptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine.
TiboloneMethylphenidate may decrease the antihypertensive activities of Tibolone.
TiclopidineThe metabolism of Methylphenidate can be decreased when combined with Ticlopidine.
TicrynafenMethylphenidate may decrease the antihypertensive activities of Ticrynafen.
TimololMethylphenidate may decrease the antihypertensive activities of Timolol.
TipranavirThe metabolism of Methylphenidate can be decreased when combined with Tipranavir.
TolazolineMethylphenidate may decrease the antihypertensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypertensive activities of Methylphenidate.
TorasemideMethylphenidate may decrease the antihypertensive activities of Torasemide.
TrandolaprilMethylphenidate may decrease the antihypertensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methylphenidate.
TranylcypromineTranylcypromine may increase the hypertensive activities of Methylphenidate.
TravoprostMethylphenidate may decrease the antihypertensive activities of Travoprost.
TreprostinilMethylphenidate may decrease the antihypertensive activities of Treprostinil.
TrichlormethiazideMethylphenidate may decrease the antihypertensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.
TrimazosinMethylphenidate may decrease the antihypertensive activities of Trimazosin.
TrimethaphanMethylphenidate may decrease the antihypertensive activities of Trimethaphan.
TrimipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
UnoprostoneMethylphenidate may decrease the antihypertensive activities of Unoprostone.
ValsartanMethylphenidate may decrease the antihypertensive activities of Valsartan.
VenlafaxineThe metabolism of Methylphenidate can be decreased when combined with Venlafaxine.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Methylphenidate.
XylometazolineMethylphenidate may decrease the antihypertensive activities of Xylometazoline.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take on empty stomach: 1 hour before or 2 hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66. [PubMed:10025684 ]
  2. Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74. [PubMed:10037500 ]
  3. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  4. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12. [PubMed:10403500 ]
  5. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  8. Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114. [PubMed:15303308 ]
  9. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8. [PubMed:15322419 ]
  2. Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51. [PubMed:17218796 ]
  3. Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24. [PubMed:16246598 ]
  4. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207. [PubMed:17611273 ]
  5. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9. [PubMed:11160413 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  2. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  3. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7. [PubMed:17154506 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Carboxylic ester hydrolase activity
Specific Function:
Not Available
Gene Name:
CES1A1a
Uniprot ID:
Q6LAP9
Molecular Weight:
1908.25 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28